Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency

drug protocol number
Forma 02
drug sponsor
Octapharma
drug study
Octafibrin
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Ongoing
drug phase